Edition:
United Kingdom

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

2.32USD
20 Mar 2019
Change (% chg)

-- (--)
Prev Close
$2.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
75,371
52-wk High
$5.10
52-wk Low
$2.03

Chart for

About

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's... (more)

Overall

Beta: 0.45
Market Cap(Mil.): $165.38
Shares Outstanding(Mil.): 31.35
Dividend: --
Yield (%): --

Financials

  ADMP.OQ Industry Sector
P/E (TTM): -- 29.30 32.54
EPS (TTM): -0.89 -- --
ROI: -68.80 14.23 13.82
ROE: -79.58 15.46 15.25

BRIEF-Adamis Pharmaceuticals’ Commercial Partner Launches Symjepi (Epinephrine) In The US

* ADAMIS’ COMMERCIAL PARTNER LAUNCHES SYMJEPI™ (EPINEPHRINE) IN THE US

16 Jan 2019

Swiss stocks - Factors to watch on Dec. 7

ZURICH/BERLIN, Dec 7 The Swiss blue-chip SMI was seen opening 1.2 percent higher at 8,765 points on Friday, according to premarket indications by bank Julius Baer .

07 Dec 2018

Novartis to launch Adamis' EpiPen rival in U.S. next year

Dec 6 Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

07 Dec 2018

BRIEF-Adamis Pharmaceuticals Provides Update On Symjepi's U.S. Launch

* ADAMIS PHARMACEUTICALS PROVIDES UPDATE ON THE U.S. LAUNCH OF SYMJEPI

06 Dec 2018

Earnings vs. Estimates